Drug Delivery Systems for Metabolic Disorders

Drug Delivery Systems for Metabolic Disorders

1st Edition - August 26, 2022

Write a review

  • Editors: Harish Dureja, Narasimha Murthy, Peter Wich, Kamal Dua
  • Paperback ISBN: 9780323996167
  • eBook ISBN: 9780323996334

Purchase options

Purchase options
DRM-free (EPub, PDF)
Sales tax will be calculated at check-out

Institutional Subscription

Free Global Shipping
No minimum order


Drug Delivery Systems for Metabolic Disorders presents the most recent developments on the targeted delivery of drugs to deal with metabolic disorders in a safe, compliant and continuous way. The book covers recent developments in advanced drug delivery systems in various metabolic disorders, including disturbances in protein, lipid, carbohydrate and hormone metabolism and lysosomal and mitochondrial disorders. It provides a brief introduction to metabolic disorders, along with a focus on the current landscape and trends in understanding disease pathology using different in vitro and in vivo models required for clinical applications and developments of new therapeutics. Each subsequent chapter covers drug delivery systems dedicated to metabolic diseases caused by disturbances in protein, lipid, carbohydrate and hormone metabolism. Then, it moves on to cover lysosomal storage disorders and applications of phytopharmaceuticals in this context. This is the perfect reference for researchers in pharmaceutical science who are interested in developing new treatments for metabolic diseases.

Key Features

  • Offers comprehensive coverage of drug delivery to treat metabolic diseases
  • Provides insights into how advanced drug delivery systems can be effectively used for the management of various types of metabolic disorders
  • Includes the most recent research on diagnostic methods and treatment strategies using controlled drug delivery systems


Pharmaceutical scientists at PhD level and above in academia and industry. Scientists in metabolic disorders, Nanobiotechnology, Molecular Biology; Research Physicians in metabolic disorders

Table of Contents

  • Cover image
  • Title page
  • Table of Contents
  • Copyright
  • List of contributors
  • About the editors
  • Chapter 1. Introduction to metabolic disorders
  • Abstract
  • 1.1 Metabolic disorders due to deregulation of protein/amino acid metabolism
  • 1.2 Metabolic disorders due to deregulation of lipid metabolism
  • 1.3 Metabolic disorder due to deregulation in carbohydrate metabolism
  • 1.4 Metabolic disorder due to disturbance in hormone metabolism
  • 1.5 Metabolic disorder due to deregulation in lysosomal storage disorders
  • 1.6 Metabolic disorder due to deregulation in mitochondrial disorders
  • References
  • Further reading
  • Chapter 2. Cellular and molecular mechanisms involved in metabolic disorders
  • Abstract
  • 2.1 Introduction
  • 2.2 Alterations in single-minded protein-1: downstream mediator of leptin-melanocortin pathway
  • 2.3 Link between osteocalcin deficiency and insulin resistance
  • 2.4 Aberrations in the JAK-STAT pathway
  • 2.5 Alteration in AMPK activity: insulin resistance and cardiovascular problems
  • 2.6 Conclusion
  • Acknowledgments
  • References
  • Chapter 3. Current practices in drug delivery for metabolic disorders
  • Abstract
  • 3.1 Introduction
  • 3.2 Oral drug delivery approaches
  • 3.3 Site-specific drug delivery approaches
  • 3.4 Targeted drug delivery
  • 3.5 Intelligent drug delivery
  • 3.6 Conclusion
  • Acknowledgments
  • References
  • Chapter 4. Recent developments in the treatment of amyloidosis
  • Abstract
  • 4.1 Introduction
  • 4.2 The history of amyloidosis
  • 4.3 Amyloid fibril
  • 4.4 Conclusion
  • Acknowledgments
  • References
  • Chapter 5. Advanced drug delivery systems targeting to improve therapeutic outcomes in porphyria
  • Abstract
  • 5.1 Introduction
  • 5.2 Prevalence
  • 5.3 Pathophysiology
  • 5.4 Symptoms and diagnosis
  • 5.5 Treatment strategies
  • 5.6 Overview of treatment drugs and current treatment problems
  • 5.7 Novel therapies
  • 5.8 Summary and conclusion
  • References
  • Chapter 6. Advanced drug delivery systems targeting kwashiorkor involving a disturbance in protein metabolism
  • Abstract
  • 6.1 Introduction
  • 6.2 Physiological changes associated with kwashiorkor disease
  • 6.3 Biochemical manifestations and metabolic disorders associated with kwashiorkor disease
  • 6.4 Signs, symptoms, and clinical manifestations in kwashiorkor
  • 6.5 Current treatment of kwashiorkor
  • 6.6 Metabolic disturbances associated with kwashiorkor
  • 6.7 Role of nanotechnology in drug-delivery
  • 6.8 Different types of drug delivery vehicles
  • 6.9 Advanced drug delivery system targeting kwashiorkor
  • 6.10 Conclusion
  • References
  • Chapter 7. Advanced drug delivery systems targeting metabolic disorders: erythropoietic protoporphyria
  • Abstract
  • 7.1 Introduction
  • 7.2 Etiology
  • 7.3 Clinical features
  • 7.4 Diagnosis
  • 7.5 Pathophysiology
  • 7.6 Genotype-phenotype correlations
  • 7.7 Current and emerging therapies
  • 7.8 Conclusion and future perspective
  • References
  • Chapter 8. Combating atherosclerosis with nanodrug delivery approaches: from bench side to commercialization
  • Abstract
  • 8.1 Introduction
  • 8.2 Atherosclerosis
  • 8.3 Nanoformulations for the treatment of atherosclerosis with implementation of quality by design
  • 8.4 Dendrimers
  • 8.5 Challenges in translating nanodrug delivery systems from bench to bedside
  • 8.6 Conclusion
  • References
  • Chapter 9. Advanced drug delivery systems in the management of Gaucher disease
  • Abstract
  • 9.1 History
  • 9.2 Epidemiology
  • 9.3 Etiology
  • 9.4 Pathogenesis
  • 9.5 Clinical classification of Gaucher disease
  • 9.6 Management of Gaucher disease
  • 9.7 Conclusion
  • References
  • Chapter 10. Advanced drug delivery systems focusing the metabolic disorders due to deregulation of lipid metabolism: Niemann Pick Disease and Letterer-Siwe disease
  • Abstract
  • 10.1 Introduction
  • 10.2 Neimann’s Pick disease
  • 10.3 Etiology
  • 10.4 Stage 1: early lesion’s phase
  • 10.5 Stage 2: fibrous phase
  • 10.6 Stage 3: extra lesion phase
  • 10.7 Diagnosis Letterer Siwe disease
  • 10.8 Prospects
  • 10.9 Conclusion
  • References
  • Chapter 11. Genetic disease and Niemann-Pick disorders: novel treatments and drug delivery systems
  • Abstract
  • 11.1 Introduction to genetic disorders
  • 11.2 Classification of inherited metabolic disorders
  • 11.3 Physiology of lipid metabolism and diseases associated with lipid metabolism
  • 11.4 Essential aspects of Niemann-Pick disease: prevalence, pathophysiology, diagnosis, and symptoms
  • 11.5 Current therapeutic strategies to treat Niemann-Pick disease
  • 11.6 Problems associated with the current therapeutic strategies to treat Niemann-Pick disease
  • 11.7 Possible novel drug delivery systems to improve therapeutic efficacy in Niemann-Pick disease
  • References
  • Chapter 12. Novel 3D printing drug delivery system for the prevention and treatment of Atherosclerosis
  • Abstract
  • 12.1 Importance of 3D printing drug delivery systems
  • 12.2 Pathophysiology of atherosclerosis
  • 12.3 Drugs used for the prevention and treatment of atherosclerosis
  • 12.4 Problems with current oral drug delivery
  • 12.5 Customized 3D printed dosage forms for atherosclerosis and associated diseases
  • 12.6 Conclusion
  • References
  • Chapter 13. Advanced drug delivery systems to treat Huntington’s disease: challenges and opportunities
  • Abstract
  • 13.1 Introduction
  • 13.2 Global prevalence and economic burden
  • 13.3 Pathophysiology
  • 13.4 Pharmacological management of Huntington’s disease
  • 13.5 Herbal therapy
  • 13.6 Challenges associated with conventional therapy and the need for advanced drug delivery systems
  • 13.7 Conclusion and perspectives
  • References
  • Chapter 14. Advanced drug delivery systems for targeting obesity
  • Abstract
  • 14.1 Introduction
  • 14.2 Reason for weight gain
  • 14.3 Obesity management
  • 14.4 Conventional anti-obesity treatments
  • 14.5 Advanced drug delivery systems
  • 14.6 Conclusion and future prospectus
  • References
  • Chapter 15. Advanced drug delivery systems for treatment of diabetes mellitus
  • Abstract
  • 15.1 Introduction
  • 15.2 Antidiabetic medication-related complications
  • 15.3 Possibilities provided by the various Novel drug delivery systems
  • 15.4 Development and designing of various advanced drug delivery systems for diabetes treatment
  • 15.5 Prospects and conclusion
  • References
  • Chapter 16. Advanced drug delivery system in the treatment of hyperglycemia and hypoglycemia
  • Abstract
  • 16.1 Introduction
  • 16.2 Conventional treatment for glucose metabolism disorders
  • 16.3 Alternative approaches to diabetes
  • 16.4 Nanomaterials for treatment of diabetes
  • 16.5 Advances in insulin delivery
  • 16.6 Conclusion and future perspectives
  • References
  • Chapter 17. Emerging drug delivery in the treatment of hyperpituitarism and hypopituitarism
  • Abstract
  • 17.1 Introduction
  • 17.2 Treatment of hypopituitarism and hyperpituitarism
  • 17.3 Conclusion and future perspective
  • References
  • Chapter 18. Advance drug delivery systems targeting hypoparathyroidism and hyperparathyroidism
  • Abstract
  • 18.1 Introduction
  • 18.2 Pathophysiology
  • 18.3 Clinical manifestations
  • 18.4 Current treatments for hypoparathyroidism and hyperparathyroidism
  • 18.5 Conclusion
  • References
  • Chapter 19. An update on the development of advanced drug delivery systems for the treatment of hyperthyroidism
  • Abstract
  • 19.1 Introduction
  • 19.2 Epidemiology of hyperthyroidism
  • 19.3 Common etiology and pathogenesis of hyperthyroidism
  • 19.4 Diagnosis of hyperthyroidism
  • 19.5 Advancement in drug delivery systems/techniques for the management of hyperthyroidism
  • 19.6 Potential future therapies
  • 19.7 Nanoparticles: promising auxiliary agents for therapy of hyperthyroidism and associated diseases
  • 19.8 Conclusions and future perspectives
  • References
  • Chapter 20. Advanced drug delivery systems involving lysosomal storage disorders for Schinder disease and other disorders
  • Abstract
  • 20.1 Introduction to lysosomal storage disorders
  • 20.2 Potential targets for lysosomal disorders
  • 20.3 Potential strategies using advanced delivery systems for lysosomal storage diseases
  • 20.4 Attempts in treatment of lysosomal storage diseases by utilization of gene therapy
  • 20.5 Current novel lysosomal storage disorder therapies in clinical trials
  • Acknowledgments
  • References
  • Chapter 21. Advanced drug delivery systems involving lysosomal storage disorders for Fabry disease
  • Abstract
  • 21.1 Introduction
  • 21.2 Classification and clinical manifestations
  • 21.3 Diagnosis
  • 21.4 Treatments
  • 21.5 New approaches for the treatment of Fabry disease
  • 21.6 Advanced drug delivery systems in Fabry disease
  • 21.7 Conclusion
  • References
  • Chapter 22. Drug delivery systems in Krabbe disease—present and prospective approaches
  • Abstract
  • 22.1 Introduction
  • 22.2 Genetic background
  • 22.3 Pathophysiology
  • 22.4 Current approaches and challenges
  • 22.5 Potential targets and approaches
  • 22.6 Conclusion
  • References
  • Chapter 23. Strategies to combat Tay-Sachs disease
  • Abstract
  • 23.1 Introduction
  • 23.2 Overview of Tay-Sachs disease
  • 23.3 Treatment strategies and management
  • 23.4 Developmental treatment for Tay-Sachs disease
  • 23.5 Conclusion
  • References
  • Chapter 24. Sandhoff disease: pathology and advanced treatment strategies
  • Abstract
  • 24.1 Lysosomal storage disease
  • 24.2 Sandhoff disease
  • 24.3 Etiology and pathogenesis
  • 24.4 Prevalence and occurrence
  • 24.5 Clinical characteristics
  • 24.6 Treatment
  • 24.7 Carriers for lysosomal drug delivery
  • 24.8 Liposomes
  • 24.9 Future developments on sandhoff disease
  • 24.10 Conclusion
  • References
  • Chapter 25. Nanomaterials-based drug delivery approaches for metabolic disorders
  • Abstract
  • 25.1 Introduction
  • 25.2 Routes of drug delivery for metabolic disorders
  • 25.3 Nanomaterial-based drug delivery approaches
  • 25.4 Applications of nano-based drug delivery systems to treat metabolic disorders
  • 25.5 Limitations of using nano-based drug delivery approach
  • 25.6 Future prospective
  • 25.7 Conclusion
  • References
  • Chapter 26. Eye in metabolic disorders: manifestations and drug delivery systems
  • Abstract
  • 26.1 Introduction
  • 26.2 Diabetic retinopathy (Dr)
  • 26.3 Glaucoma
  • 26.4 Cataract
  • 26.5 Conclusion
  • References
  • Chapter 27. Advanced drug delivery systems involving mitochondrial disorders
  • Abstract
  • 27.1 Introduction
  • 27.2 Mitochondrial DNA
  • 27.3 Clinical manifestations of mitochondrial disorders
  • 27.4 Mitochondrial diseases
  • 27.5 Delivery systems for mitochondrial diseases
  • 27.6 Peptide-based mitochondrial-targeted strategy
  • 27.7 Mitochondrial targeting sequences
  • 27.8 Szeto–Schiller peptides
  • 27.9 Vehicle-based mitochondrial-targeted strategy
  • 27.10 MITO-Porter
  • 27.11 Mesoporous silica nanoparticles
  • 27.12 Conclusions
  • References
  • Chapter 28. Applications of phytopharmaceuticals in targeting metabolic disorders
  • Abstract
  • 28.1 Introduction
  • 28.2 Role of polyphenols and terpenoids in the treatment of metabolic disorders
  • 28.3 Management of metabolic disorders via phytomedicinal therapy
  • 28.4 Future prospective of phytopharmaceuticals for metabolic disorders
  • 28.5 Conclusion
  • References
  • Chapter 29. Phytonanoparticles toward the treatment of diabetes
  • Abstract
  • 29.1 What is diabetes?
  • 29.2 Classification and treatment available for diabetes
  • 29.3 Treatment available for diabetes
  • 29.4 Nanoparticles for the treatment of diabetes
  • 29.5 Advantages of phytoderived nanoparticles
  • 29.6 List of nanoparticles for the treatment of diabetes
  • 29.7 List of phytonanoparticles for the treatment of diabetes
  • 29.8 Conclusion
  • Acknowledgments
  • References
  • Chapter 30. Role of nutraceuticals in metabolic syndrome
  • Abstract
  • 30.1 Introduction
  • 30.2 Definition, pathogenesis, and pathophysiology of metabolic syndrome
  • 30.3 Applications of nutraceuticals in the management of Ms
  • 30.4 Conclusion
  • References
  • Chapter 31. Latest advances of phytomedicine in drug delivery systems for targeting metabolic disorders
  • Abstract
  • 31.1 Introduction
  • 31.2 Significance of phytomedicines as therapeutics
  • 31.3 Pathophysiology of metabolic syndrome
  • 31.4 Phytomedicines in drug delivery system
  • 31.5 Future perspective
  • 31.6 Conclusion
  • References
  • Chapter 32. Clinical trials, future prospects and challenges of drug delivery in combating metabolic disorders
  • Abstract
  • 32.1 Challenges faced by advanced delivery systems
  • 32.2 Future prospects
  • 32.3 Conclusion
  • References
  • Index

Product details

  • No. of pages: 526
  • Language: English
  • Copyright: © Academic Press 2022
  • Published: August 26, 2022
  • Imprint: Academic Press
  • Paperback ISBN: 9780323996167
  • eBook ISBN: 9780323996334

About the Editors

Harish Dureja

Dr. Harish Dureja is Professor and Head, Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak. Dr. Dureja is also the Director, Centre for IPR Studies and Director, Professional Consultancy Cell. Dr. Dureja has more than 22 years of teaching experience. He also holds 18 years research experience in the field of nanoparticulate drug delivery, regulatory affairs and in silico ADME modeling. Dr. Dureja has been awarded with Gold-Medal for the best Ph.D. thesis and research projects worth 1.2 Crore from various funding agencies. He has filed an Indian patent and written a book and authored more than twenty five book chapters. He has published 265 publications in various international and national journals of repute. He worked as Chairman-Scientific Services Committee (LOC) during 69th IPC at Chitkara University, Raj-pura. He also worked as content writer for e-Pathashala program of Ministry of Human Resources Development for Post Graduate course of Pharmaceutical Sciences for the paper novel drug delivery system. He has delivered more than 180 invited Lectures in various conferences, seminars and symposiums and has guided 60 PG scholars and 10 students for doctoral work. He has been awarded the Gold-Medal for Best Ph.D. Thesis, Best Paper Award - Prof. M.L. Khorana Memorial Prize Award – 2005 and Dr. R.L. Nicore award - 2018. He has published six special issues as a Guest Editor for the Journals published by Bentham Science Publishers, and one issue published by Frontiers, Switzerland. He is currently also serving as President, Association of Pharmaceutical Teachers of India (APTI), Haryana State Branch.

Affiliations and Expertise

Professor, Department of Pharmaceutical Sciences, Maharshi Dayanand University

Narasimha Murthy

Dr. S. Narasimha Murthy is the CSO of Topical Products Testing LLC, USA. He was former Professor of Pharmaceutics and Drug Delivery at the University of Mississippi School of Pharmacy, USA for over 15 years. Dr. Murthy is a pioneer in nanotechnology-based delivery systems, microneedles and microstructured delivery technologies of drug delivery and diagnosis, dermal and transdermal delivery of drugs and nose to brain delivery of therapeutics. His research programs are funded by NIH, FDA, and Pharmaceutical companies. He has published over 130 research papers and presented over 250 scientific posters in various national and international scientific meetings. He has authored two books and over fifteen book chapters. He is serving on the Editorial Board of several journals including AAPS Pharm Sci Tech, DDIP and J Pharm. Sci. He is a consultant to pharmaceutical and medical device companies in the USA, Israel, Italy, and India. Dr. Murthy has received several awards such as the New Investigator award and Cumberl and Researcher of the year from the University of Mississippi, Global Indus Technovator award from MIT, Endowed Chair for Research at the Ohio Northern University and he was inducted as the Fellow of the American Association of Pharmaceutical Scientists in 2017 and was bestowed with Distinguished Scientist award by American Association of Indian Pharmaceutical Scientists. Dr. Murthy is also a scientific philanthropist. He is the Founder Director of a non-profit research organization, Institute for Drug Delivery and Biomedical Research in Bangalore, India (www.IDBresearch.com).

Affiliations and Expertise

Professor of Pharmaceutics and Drug Delivery, University of Mississippi, USA

Peter Wich

Dr. Peter Wich leads the Research Lab for Functional Biopolymers at the University of New South Wales in Sydney (Australia). His primary research interests are in the fields of macromolecular chemistry at the interface between nanotechnology and bioorganic chemistry. His lab focuses on the chemical modification of natural biopolymers with the aim to engineer new multi-functional and biocompatible materials for applications in drug delivery, nanomedicine, bio-catalysis, and 3D printing. Dr. Wich is an expert in the field of biopolymer modification and the (self) assembly of these new biohybrid materials into nanoparticles for dynamic drug delivery systems. Dr. Wich has been awarded more than 20 prizes and scholarships for his research, including the Innovation Prize in Medicinal/Pharmaceutical Chemistry for his work on bioinspired nanomaterials (jointly awarded by the Awarded by the German Chemical and the German Pharmaceutical Society) and the Galenus Technology Prize, for his innovative achievements in the field of Pharmaceutical Technology. In 2016, he was selected as “Young Member” of the Academy of Sciences and Literature in Mainz, Germany. In recognition of his achievements, he was selected in 2019 to represent the element Roentgenium in the IUPAC Periodic Table of Younger Chemists. In 2019 Peter was named Emerging Investigator of the Journal “Soft Matter” and in 2020 he was selected as Polymer Chemistry Emerging Investigator.

Affiliations and Expertise

Senior Lecturer and Junior Professor for Bioorganic & Macromolecular Chemistry, School of Chemical Engineering, University of New South Wales,

Kamal Dua

Dr. Kamal Dua is a Senior Lecturer in the Discipline of Pharmacy at the Graduate School of Health, University of Technology Sydney (UTS), Australia. He has research experience of over 12 years in the field of drug delivery systems targeting inflammatory diseases. Dr. Dua is also a Node Leader of Drug Delivery Research in the Centre for Inflammation at Centenary Institute/UTS, where the targets identified from the research projects are pursued to develop novel formulations as the first step towards translation into clinics. Dr. Dua researches in two complementary areas; drug delivery and immunology, specifically addressing how these disciplines can advance one an-other, helping the community to live longer and healthier. This is evidenced by his extensive publication record in reputed journals. Dr. Dua’s research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as Interleukins and microRNAs and developing new and effective drug delivery formulations for the management of chronic airway diseases. He has published more than 80 research articles in peer-reviewed international journals and authored or co-authored four books. He is an active member of many national and international professional societies.

Affiliations and Expertise

Senior Lecturer, Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia

Ratings and Reviews

Write a review

There are currently no reviews for "Drug Delivery Systems for Metabolic Disorders"